Blog

Hemofilia

Koāte: Usos, dosis, efectos secundarios, advertencias y precio

Mano enguantada sosteniendo un tubo de ensayo con Factor VII, que se reemplaza cuando un paciente usa Koāte.

Koāte-DVI (also marketed as KOĀTE) is an FDA-approved injectable drug used for the control and prevention of bleeding in people with hemofilia A. It works by temporarily replacing the clotting factor VIII protein and helps the blood clot properly.  

Obtenga asistencia con el copago ahora

(877) 778-0318

Koāte-DVI is also known by its generic name, antihemophilic factor (human), meaning it is derived from donated human plasma. Koāte-DVI belongs to the coagulation factors and hemostatic drug class and is only available with a doctor’s prescription. 

This article discusses everything you need to know about Koāte-DVI, including its uses, benefits, recommended dose, possible side effects, and important safety information. 

Indicación

Koāte-DVI (antihemophilic factor [human]) is used to control and prevent bleeding episodes in people with hemophilia A. It is also used to manage bleeding during emergency or elective surgery in people with hemophilia A. 

This drug is not indicated for the treatment of enfermedad de von Willebrand. 

Mecanismo de acción

In patients with hemophilia A, the clotting factor VIII is either missing or not functioning properly. As a result, people with hemophilia A may bleed longer and more frequently than people with a normal amount of clotting factor VIII in their body. 

Koāte-DVI, a human plasma-derived Factor VIII, temporarily replaces the missing or nonfunctional clotting factor VIII when infused and helps control bleeds in people with hemophilia A. The half-life of Koāte-DVI can vary between patients. 

Koāte-DVI: Drug Form

Koāte-DVI is available as a lyophilized powder for reconstitution in single-use vials containing 250 IU (yellow), 500 IU (blue), and 1,000 IU (red) of Factor VIII activity. 

Every vial of Koāte-DVI comes with a Mix2Vial transfer device, allowing for needle-free reconstitution. You can ask your healthcare provider about the Mix2Vial Practice Kit for step-by-step Koāte-DVI administration instructions to help you become comfortable with the reconstitution process. 

Koāte-DVI: Dosage 

The dosage and frequency of Koāte-DVI are adjusted according to the patient’s clinical condition, the severity of the Factor VIII deficiency, and the location and extent of bleeding. 

Koāte-DVI Dosage by Type of Bleeding Episodes

The recommended dosage of Koāte-DVI based on the type of bleeding is as follows:

Sangrado leve

If you experience a minor bleed such as large bruises, significant cuts or scrapes, or uncomplicated joint hemorrhage, a dose of 15 IU/kg may be given every 12 hours until bleeding stops and healing occurs (usually 1–2 days). 

Sangrado moderado

If you experience moderate bleeding (e.g., from the nose, mouth, or gums), dental extractions, or hematuria, a dose of 25 IU/kg may be given every 12 hours until healing occurs (an average of 2–7 days). 

Sangrado mayor

If you experience major bleeding such as joint or muscle hemorrhage, major trauma, hematuria, or intracranial or intraperitoneal bleeding, an initial dose of 40–50 IU/kg may be given, followed by a maintenance dose of 25 IU/kg every 12 hours. Treatment may continue until healing is achieved, for up to 10 days. Intracranial bleeding may require prophylactic therapy for up to 6 months. 

Habla con un especialista

Acerca de la asistencia para copagos
Empezar

Koāte-DVI Dosage for Surgery 

The recommended dosage of Koāte-DVI for surgery is as follows: 

  • Before surgery, you may receive a dose of 40–50 IU/kg once to achieve an FVIII level of 80–100%.
  • After surgery, a dose of 30–50 IU/kg every 12 hours is recommended to maintain FVIII levels of 60–100% for 7–10 days or until healing is achieved.

How Koāte-DVI Is Given

Koāte-DVI is given intravenously (IV) after the powder is mixed with sterile water. Follow your healthcare provider’s instructions for preparing and administering Koāte-DVI. 

The prepared solution should be used within 3 hours and should not be refrigerated after mixing. The IV administration rate should not exceed 10 ml per minute. Your healthcare provider will adjust the administration rate according to your tolerance and condition. 

Efectos secundarios

The most common side effects associated with Koāte-DVI infusion include:

Man clutching stomach, experiencing abdominal pain after using Koāte-DVI
  • Nerviosismo
  • Dolor de cabeza
  • Abdominal pain (stomach ache)
  • Náuseas
  • Tingling sensation, “pins and needles” in your face, arms, or ears
  • Visión borrosa

Efectos secundarios graves

While less common, it is possible that you may experience severe allergic reactions to Koāte-DVI. The common signs and symptoms of allergic reactions are as follows:

  • Urticaria
  • Opresión en el pecho
  • sibilancias
  • Dificultad para respirar
  • Feeling light-headed
  • Desmayo
  • Hinchazón de la cara, labios, lengua o garganta.
  • calambres estomacales
  • Dolor articular
  • Presión arterial baja

Get immediate medical help if you experience symptoms of a severe allergic reaction. In that case, your healthcare provider will discontinue the Koāte-DVI treatment and administer the appropriate treatment. 

¿Califica usted para el copago $0?

Descúbrelo ahora
(877) 778-0318

Advertencias y precauciones

There are some important warnings and precautions to be aware of before starting and during treatment with Koāte-DVI: 

  • Develop Factor VIII inhibitors: Your body may make antibodies that reduce or stop Koāte-DVI from working properly. Tell your healthcare provider if the medicine does not control your bleeding as well as expected.
  • Develop anemia from red blood cell breakdown: Large or frequent doses of Koāte-DVI may cause red blood cells to break down, especially if you have blood type A, B, or AB. Your healthcare provider may do blood tests to check for this problem.
  • Transmission of infectious agents: Because Koāte-DVI is made from human blood, it may carry a risk of transmitting infectious agents. Measures are used during manufacturing to reduce this risk, but the possibility of transmitting infectious diseases cannot be completely eliminated. 

Information to Tell Your Healthcare Provider

To make sure Koāte-DVI treatment is safe for you, it is important to share your medical history with your doctor. Tell your healthcare provider if you:

  • Are pregnant or plan to become pregnant (because there are not enough data to determine the drug-associated risk during pregnancy) 
  • Are breastfeeding (because it is not known whether Koāte-DVI passes into human milk or affects a breastfed baby or milk production) 
  • Have any planned surgeries or dental procedures
  • ¿Está tomando algún medicamento de venta libre u otros factores de coagulación, suplementos o productos a base de hierbas?
  • Me han dicho que tienes inhibitors to factor VIII because Koāte-DVI may not work for you

Koāte-DVI: Cost

The cost of Koāte-DVI can vary depending on your Factor VIII requirements, body weight, treatment frequency, insurance coverage, and the number of vials needed. 

Eligible patients with commercial insurance and financial need may qualify for the manufacturer’s copay assistance program, subject to program terms and eligibility requirements. Contáctanos if you are interested in exploring financial assistance or copay assistance for Koāte-DVI.

The manufacturer also offers the KOĀTE TRY-IT Program, which allows eligible patients to try Koāte-DVI for up to 2 weeks at no cost, with a maximum of 50,000 IU. To qualify, patients must not currently be using Koāte-DVI and must not have a currently diagnosed Factor VIII inhibitor.

REFERENCIAS:

  1. Administración de Alimentos y Medicamentos de los Estados Unidos (FDA). Koāte-DVI, [Human]) Prescribing Information: https://www.fda.gov/media/190221/download
  2. KOATE-DVI FOR INJECTION 250 IU/5 ML [SIN11785P]. (n.d.). National Drug Formulary. https://www.ndf.gov.sg/about-drugs/product-information/sin11785p/#ce8bf04d3522b1442886b2d0d245cf31
  3. Escobar, M. A., Shaffer, L., Holguin, M., McCavit, T., Rajan, S. K., & Amega, N. (2019). Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia A and Inhibitors: A Retrospective Study. Sangre, 134, 4923. https://doi.org/10.1182/blood-2019-122949 
  4. KOATE. (n.d.). Patient Information Guide: https://www.mykoate.com/pdfs/KOATE%20Prescribing%20Information.pdf
  5. Antihemophilic factor (human): Koate-DVI. Package insert. Grifols Therapeutics Inc. Accessed August 30, 2026. 
Esta información no sustituye el consejo ni el tratamiento médico. Consulte a su médico o profesional de la salud sobre su afección médica antes de comenzar cualquier tratamiento nuevo. AmeriPharma® Specialty Care no asume ninguna responsabilidad por la información proporcionada ni por ningún diagnóstico o tratamiento realizado como resultado, ni se responsabiliza de la fiabilidad del contenido. AmeriPharma® Specialty Care no opera todos los sitios web/organizaciones aquí mencionados, ni se responsabiliza de la disponibilidad o fiabilidad de su contenido. Estos listados no implican ni constituyen un respaldo, patrocinio ni recomendación por parte de AmeriPharma® Specialty Care. Esta página web puede contener referencias a medicamentos recetados de marca que son marcas comerciales o marcas registradas de fabricantes farmacéuticos no afiliados a AmeriPharma® Specialty Care.
Dr. Mark Alfonso
REVISADO MÉDICAMENTE POR Dr. Mark Alfonso, PharmD, BCMTMS

El Dr. Mark Alfonso, doctor en farmacia, nació y creció en Pueblo, Colorado. Obtuvo su título en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus Médico Anschutz, en 2010. Obtuvo su certificación en gestión de terapias farmacológicas en 2022. Lo más gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus áreas de especialización son la farmacia comunitaria y la gestión de terapias farmacológicas. En su tiempo libre, disfruta de la lectura y correr.

Contáctenos

Si está interesado en hablar con un especialista o desea explorar oportunidades de asistencia financiera, utilice el formulario de contacto a continuación para comunicarse con nosotros.

Cumple con la norma HIPAA

Al enviar, acepta los términos y condiciones de AmeriPharma. Condiciones de uso, política de privacidad, y Aviso de prácticas de privacidad